Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis
Fernando Luiz Barros Edington, Sandra Rocha Gadellha, Mittermayer Barreto Santiago
European Journal of Internal Medicine, doi:10.1016/j.ejim.2021.03.028
To estimate the incidence rate ratio (IRR) of adverse events (AE) in chloroquine or hydroxychloroquine users. Methods: We systematically reviewed randomized controlled trials (RCTs), using MEDLINE (2010MEDLINE ( -2020) ) and EMBASE (2010-2020) databases, reporting AE in chloroquine or hydroxychloroquine users during treatment for lupus, rheumatoid arthritis, malaria and COVID-19. The protocol for this systematic review is registered at the PROSPERO database (CRD42020197938). The quality of the included studies was assessed using the Cochrane risk-of-Bias tool and relevant data were extracted though a customized data collection form, independently, by two authors. The IRR of AE was estimated using a random-effect model meta-analysis and heterogeneity was evaluated by T 2 and I 2 . Subgroup analysis was performed, and publication bias was assessed by funnel-plot. Results: Forty-six RCTs met our eligibility criteria and were included in our analysis (23132 patients). There was not a single death attributed to chloroquine or hydroxychloroquine use in the included RCTs. The IRR of general AE during antimalarial use was 1.15 [CI 95% 1.01-1.31]. COVID-19 patients treated with either antimalarial presented an 83% and 165% higher risk of developing general and gastrointestinal AE, respectively, in comparison with controls. The use of antimalarial increased the risk of developing dermatological AE by 92% in malarial studies and reduced by 65% in lupus studies. We did not find a significatively higher risk of cardiovascular nor ophthalmological AE in antimalarial users. Conclusions: Our data reinforces that chloroquine and hydroxychloroquine have a good safety profile though caution is advised when using higher than usual doses in hospitalized COVID-19 patients.
Ethics approval and consent to participate As all the data used in this systematic review is available for public access, there is no need of ethics committee approval.
Consent
Not applicable. Author's contribution FLBE conceptualized, drafted and is the guarantor of this manuscript. FLBE and SG developed the selection criteria, the risk of bias assessment strategy and data extraction criteria. MBS and SG reviewed the manuscript. All authors read, provided feedback and approved this systematic review.
Declaration of Competing Interest The authors declare that they have no competing interest.
References
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Chatre, Roubille, Vernhet, Jorgensen, Pers, Cardiac Complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature, Drug Saf,
doi:10.1007/s40264-018-0689-4De Jong, Hazes, Han, Huisman, Van Zeben et al., Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial, Ann Rheum Dis,
doi:10.1136/annrheumdis-2013-204788Friedrich, Adhikari, Beyene, Inclusion of zero total event trials in metaanalyses maintains analytic consistency and incorporates all available data, BMC Med Res Methodol,
doi:10.1186/1471-2288-7-5Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Guevara, Berlin, Wolf, Meta-analytic methods for pooling rates when follow-up duration varies: a case study, BMC Med Res Methodol,
doi:10.1186/1471-2288-4-17Harvey, Cochrane, The treatment of lupus erythematosus with chloroquine sulphate1, J Invest Dermatol,
doi:10.1038/jid.1954.12Heimans, Akdemir, Boer, Goekoop-Ruiterman, Molenaar et al., Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study), Arthritis Res Ther,
doi:10.1186/s13075-015-0912-yHuang, Andrews, Jones, Skovron, Tilson, Pitfalls in meta-analyses on adverse events reported from clinical trials: PITFALLS IN META-ANALYSES ON ADVERSE EVENTS, Pharmacoepidemiol Drug Saf,
doi:10.1002/pds.2208Kingsbury, Tharmanathan, Adamson, Arden, Birrell et al., Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial, Trials,
doi:10.1186/1745-6215-14-64Kitchen, Vaughn, Skillman, Reviews of anti-infective agents: role of US military research programs in the development of US food and drug administration-approved antimalarial drugs, Clin Infect Dis,
doi:10.1086/504873Kravvariti, Koutsogianni, Samoli, Sfikakis, Tektonidou, The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102491Mao, Qiu, He, Tan, Li et al., Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol,
doi:10.1016/S2468-1253(20)30126-6Moreland, Dell, Paulus, Curtis, Bathon, A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial, Arthritis Rheum,
doi:10.1002/art.34498O'dell, Mikuls, Taylor, Ahluwalia, Brophy et al., Therapies for active rheumatoid arthritis after methotrexate failure, N Engl J Med,
doi:10.1056/NEJMoa1303006Popovici, Vantaux, Primault, Samreth, Piv et al., Therapeutic and transmission-blocking efficacy of dihydroartemisinin/piperaquine and chloroquine against Plasmodium vivax Malaria, Cambodia, Emerg Infect Dis,
doi:10.3201/eid2408.170768Prisma-P Group, Moher, Shamseer, Clarke, Ghersi et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst Rev,
doi:10.1186/2046-4053-4-1Shi, Qin, Shen, Cai, Liu et al., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China, JAMA Cardiol,
doi:10.1001/jamacardio.2020.0950Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.l4898Teixeira, Borba, Pedrosa, Nishioka, Viana et al., Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus, Europace,
doi:10.1093/europace/eut290Thuan, Ca, Van Toi, Nhien, Thanh et al., A Randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam, Am J Trop Med Hyg,
doi:10.4269/ajtmh.15-0740Van Vollenhoven, Geborek, Forslind, Albertsson, Ernestam et al., Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial, Lancet,
doi:10.1016/S0140-6736(12)60027-0Viechtbauer, Cheung, Outlier and influence diagnostics for meta-analysis, Res Synth Methods,
doi:10.1002/jrsm.11Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Zhong, Wang, Zhang, Liu, Le et al., Efficacy and safety of current therapeutic options for COVID-19 -lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis, Pharmacol Res,
doi:10.1016/j.phrs.2020.104872
